Rezolute (NASDAQ:RZLT) Releases Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Rezolute (NASDAQ:RZLT) released its quarterly earnings results on Thursday. The company reported ($0.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.14), Zacks reports.

Rezolute Trading Up 5.4 %

Shares of NASDAQ RZLT opened at $5.08 on Friday. The stock has a fifty day moving average price of $4.62 and a 200 day moving average price of $3.72. Rezolute has a 12-month low of $0.72 and a 12-month high of $6.10. The company has a market cap of $203.89 million, a P/E ratio of -4.46 and a beta of 1.18.

Wall Street Analyst Weigh In

Several research analysts have weighed in on RZLT shares. Guggenheim initiated coverage on Rezolute in a report on Tuesday, August 27th. They issued a “buy” rating and a $11.00 price target for the company. Craig Hallum assumed coverage on Rezolute in a research report on Tuesday, June 4th. They set a “buy” rating and a $14.00 target price on the stock. Maxim Group raised their price target on Rezolute from $8.00 to $10.00 and gave the stock a “buy” rating in a research note on Tuesday, August 6th. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Rezolute in a research note on Monday, September 9th. Finally, JMP Securities reissued a “market outperform” rating and issued a $7.00 target price on shares of Rezolute in a research report on Friday. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Rezolute presently has an average rating of “Buy” and a consensus price target of $11.57.

About Rezolute

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.